AIIA child-care departments made RAV centres to study Swarnaprashan safety

The All India Institute of Ayurveda (AIIA) has signed a memorandum of understanding (MoU) with Rashtriya Ayurveda Vidyapeeth (RAV) under which AIIA's Kaumarbhritya (Ayurvedic paediatrics) departments in New Delhi and Goa are recognised as RAV Centres of Excellence. The agreement was signed during KAUMARACON 2026, a national conference on Ayurvedic child health held at AIIA in New Delhi from October 15 to 17, 2026, and was announced by the institute in reports published on October 17 and 18. A main aim is to write a standard operating procedure (SOP) for Swarnaprashan, a traditional Ayurvedic practice for children, and to study its safety and efficacy.

Kaumarbhritya is the branch of Ayurveda that deals with the care of children, from newborns to adolescents. Swarnaprashan is one of its best-known practices. According to classical Ayurvedic texts attributed to Acharya Kashyapa, it involves giving a child a preparation of purified gold rubbed with honey and ghee, and it is described both as a newborn-care rite and as a supplementary feed. In recent years, many Ayurveda clinics and colleges have run Swarnaprashan camps for children, and commercial products are widely sold.

That popularity has run ahead of the evidence. Published reviews describe a small body of clinical research, much of it uncontrolled, and authors of a 2026 review noted that claimed benefits such as improved cognition are not yet established in modern paediatric practice. Researchers have repeatedly called for standardised protocols. Because the preparation contains a metal and is given to infants and young children, questions about dose, purity and long-term safety are especially important. An SOP agreed by two national Ayush institutions could, for the first time, give practitioners a common method for preparation and administration, and a basis for properly designed studies.

The agreement keeps the distinction this field needs between tradition and evidence. The tradition describes what Swarnaprashan is and how it has been given. Whether it is safe and effective in children is a question for the laboratory and clinical research the MoU sets out, which still needs approval before it begins. No result from that research has been announced.

The second agreement, with Maharishi International University in Iowa, United States, adds to India's network of academic chairs for Ayurveda abroad. The announcement did not give the chair's start date or funding.

Short-term: Expert consultations on the Swarnaprashan SOP are to be held at AIIA's Goa and New Delhi campuses. RAV, a national Ayush body, gains two recognised centres for Ayurvedic paediatrics.

Long-term: If the planned studies are approved and carried out, they could produce the first standardised safety data on Swarnaprashan from national institutions, which would guide practitioners and regulators.

Who is affected: Parents who take children for Swarnaprashan, Ayurveda paediatricians and students, Ayush regulators, and makers of Swarnaprashan products.

Parents should note that the MoU is a research and standard-setting plan, not an approval of any health claim. Decisions about a child's health should be taken with a qualified doctor.

Questions and Answers